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Objectives: This study aims to examine in-hospital gastrointestinal (GI) bleeding, its predictors and clinical outcomes, including long-term outcomes, in a national cohort of patients undergoing percutaneous coronary intervention (PCI) in England and Wales.  
Background: GI bleeding remains associated with significant morbidity, mortality and socioeconomic burden.
Methods: We examined the temporal changes in in-hospital GI bleeding in a national cohort of patients undergoing PCI between 2007-2014 in England and Wales, its predictors and prognostic consequences. Multivariate analysis was performed to identify independent risk factors between GI bleeding and 30-day mortality. Survival analysis was performed comparing patients with, and without, GI bleeding.  
Results: There were 480 in-hospital GI bleeds in 549,298 patients (0.09%). Overall, rates of GI bleeding remained stable over time but a significant decline was observed for patients with ST segment elevation myocardial infarction (STEMI). The strongest predictors of bleeding events were STEMI - odds ratio (OR) 7.28 (95% confidence interval (95% CI) 4.82-11.00), glycoprotein IIb/IIIa inhibitor use OR 3.42 (95% CI 2.76-4.24) and use of circulatory support OR 2.65 (95% CI 1.90-3.71). Anti-platelets/coagulants (clopidogrel, prasugrel and warfarin) were not independently associated with GI bleeding. GI bleeding was independently associated with a significant increase in all-cause 30-day mortality (OR 2.08 (1.52-2.83)). Patients with in-hospital GI bleed who survived to 30-days had increased all-cause mortality risk at 1 year compared to non-bleeders (HR 1.49 (1.07-2.09)). 





Percutaneous coronary intervention (PCI) has transformed the management and outcomes in the management of acute coronary syndromes and coronary artery disease1. Nevertheless, major bleeding is an important complication after PCI and is associated with a 3-fold increase in mortality, the causes of which can be broadly divided into access and non-access site related complications ADDIN EN.CITE 2,3. Gastrointestinal (GI) bleeding is the most common source of non-access site related bleeding, accounting for 61.7% of all bleeds ADDIN EN.CITE 4. Rates of in-hospital GI bleed post PCI vary from 0.16% to 3.6% ADDIN EN.CITE 5-10. Factors that influence this variability include differences in the population studied, concomitant pharmacotherapy and the manner in which bleeding events are recorded. However, few studies have attempted to investigate long-term survival after GI bleed ADDIN EN.CITE 11,12 and there are no published studies of in-hospital GI bleed and its short and long-term prognostic impact using unselected data from a national PCI database that records both clinical characteristics as well as drug therapy. Furthermore, to date no studies have examined the temporal trends in GI bleeding. 
We therefore aimed to address these knowledge gaps with particular reference to the temporal changes in in-hospital GI bleed, its predictors and clinical outcomes, including long-term outcomes, in a large unselected cohort of patients undergoing PCI in England and Wales.  

Methods
The British Cardiovascular Intervention Society (BCIS) routinely collects data on all PCI procedures in the United Kingdom. In 2011 this database collected information on 99% of all PCI procedures performed in National Health Service Hospitals in England and Wales ADDIN EN.CITE 13,14. Within this dataset 113 variables are recorded that includes demographic/clinical variables, procedural parameters and patient outcomes. For patients in England and Wales, mortality information is obtained from the Office of National Statistics using linkage with the patient’s unique National Health Service number. 
We analyzed all patients who underwent PCI in England and Wales between 1 January 2007 and 31 December 2014. Patients were excluded if their records did not contain information for both mortality and in-hospital GI bleeding. We then classified patients into one of two groups, i.e. those with and without in-hospital GI bleeding. The two outcomes were 30-day mortality and in-hospital major adverse cardiovascular events (MACE). In-hospital GI bleed were cases of GI bleeding which occurred during the index admissions for PCI which were collected in the BCIS dataset as a specific data field under the in hospital major complications section of registry and is operator reported. In-hospital MACE was defined by the composite of in-hospital death, myocardial infarction or re-infarction. Additional data were collected on participant age, sex, body mass index, current smoking status, diabetes mellitus, hypertension, hypercholesterolemia, previous myocardial infarction, previous stroke, peripheral vascular disease, renal disease, valvular heart disease, previous PCI, previous CABG, left ventricular ejection fraction group (good, moderate, poor), use of radial access, cardiogenic shock, use of circulatory support, receipt of ventilation, diagnosis (stable angina, NSTEMI/unstable angina, STEMI), target vessel for PCI (left main, left anterior descending, left circumflex, right coronary artery and graft), multivessel disease, trip vessel disease, use of glycoprotein IIb/IIIa inhibitor, anti-platelet use (clopidogrel, prasugrel, ticagrelor, ticlopidine), warfarin use, thrombolysis, year of PCI and receipt of in-hospital blood transfusion.
Descriptive statistics are presented in tables by in-hospital GI bleed status.  The in-hospital GI bleed rates over time were explored in the entire cohort and presented by subgroups based on age (<60 years, 60-80 years, >80 years), sex and diagnosis (stable angina, non-STEMI (NSTEMI)/unstable angina and STEMI). Continuous data are presented as mean and standard deviation and difference between the two groups was determined by analysis of variance. Categorical variables are presented as number and percentage and chi-squared tests were used to determine if there were differences between the two groups. We also examined trends in participants aged >80 years, female patients, diabetes and renal disease at baseline. Multiple imputations with chained equations were used to account for missing data. Using the mi impute chained function in Stata we generated 10 complete datasets with imputed data for missing data, see Supplementary Table 1. Using the imputed dataset, multiple logistic regressions were performed to identify predictors of in-hospital GI bleeding. All variables except blood transfusion and outcomes were included in this model. Ticlopidine was not included in this model because very few patients received this treatment and no bleeding events occurred in this small group. Subsequently, univariate and multivariate logistic regression was used to quantify the association of in-hospital GI bleeding with 30-day mortality and in-hospital MACE. Further subgroup analyses were performed to address those patients who received any transfusion (blood transfusion or platelet transfusion) and no transfusion. A survival analysis was determining by using Cox Proportional Hazards ratios for patients that survived to 30-days following a GI bleed and determined their mortality at 1 year compared to those without GI bleed who survived to 30-days. Two additional sensitivity analyses regarding predictors on in-hospital GI bleeding focused on patients who had renal disease at baseline and patients with STEMI. Statistical analysis was performed using propriety software (Stata/MP version 14.0, Stata Corp, College Station, Texas, USA). The reporting of the manuscript was done in according to STROBE statement (Supplementary Table 2). As an additional analysis, we examined the predictors of death a 1 year among survivors at 30-days.

Results
A total of 549,298 patients were included in the analysis with 480 in-hospital GI bleeding events recorded (0.09%), see Table 1. Supplementary Figure 1 shows the flow diagram of participant inclusion and Supplementary Table 2 describes the extent of missing data for individual variables included in the analysis. 
Rates of GI bleed have remained stable over time in the overall cohort, 0.08% in 2007 and 0.07% in 2014 (p=0.58), as well as sub-groups, see Figure 1 and Supplementary Figure 2 and Supplementary Table 3. Temporal trends remained stable for participants in all the age subgroups <60 years (0.05% in 2007 and 0.04% in 2014, p=0.88), 60-80 years group (0.09% in 2007 and 0.07% in 2014, p=0.42) and >80 years (0.21% in 2007 and 0.18% in 2014, p=0.67). Similarly, temporal trends over time remained stable by sex, for example in-hospital GI bleed among women was 0.10% in 2007 and 0.07% in 2014 (p=0.52, across all years). In contrast, a marked decline was observed for in-hospital GI bleeding in patients with STEMI, in whom the bleeding rate declined from 0.52% in 2007 to 0.17% in 2014 (p<0.001, across all years). We observed demographic changes over time in our cohort, which included rises in the proportion of patients >80 years and the prevalence rates of diabetes and renal disease, see Supplementary Table 4.
Table 1 shows the baseline characteristics of participants according to in-hospital GI bleed status. Patients with GI bleeding were older (72 years vs 65 years, p<0.001), more likely to be female (31% vs 26%, p=0.005), more likely to have lower body mass index (27.7 vs 28.4 kg/m2, p=0.009), more likely to have hypertension (61% vs 52%, p=0.004), previous stroke (7% vs 4%, p=0.005), peripheral vascular disease (10% vs 5%, p<0.001), renal disease (8% vs 3%, p<0.001) and valvular heart disease (4% vs 1%, p<0.001). These patients were also more likely to have hemodynamic instability, with a greater prevalence of cardiogenic shock (20% vs 2%, p<0.001), the requirement for circulatory support (18% vs 2%, p<0.001) or ventilatory support (6% vs 2%, p<0.001). However, they were less likely to have had a previous PCI (17% vs 23%, p=0.002) with radial access (43% vs 50%, p=0.003). Compared to other patients with different diagnoses, the proportion of patients presenting with STEMI was higher among patients with in-hospital GI bleeding complications (68% vs 23%). When differences in medications were considered, patients with an in-hospital GI bleed were less likely to receive clopidogrel (82% vs 85%) and more likely to receive glycoprotein IIb/IIIa inhibitors (63% vs 22%), prasugrel (9% vs 4%, p<0.001), warfarin (3% vs 1%, p=0.002) and thrombolysis (7% vs 1%, p<0.001). The patient characteristics according to GPI use is shown in Supplementary Table 5. The patients who received GPI were more likely to have a diagnosis of STEMI and had a higher crude 30-day mortality and in-hospital MACE.
In the entire cohort, in-hospital GI bleed was associated with a prolonged hospital stay 11.3±15.0 days vs 2.0±5.3 days (p<0.001). In all subgroups, the occurrence of in-hospital GI bleeding was associated with significantly longer stay, see Supplementary Table 6. Among patients age <60 years, the length of stay was 1.8±4.8 days in those without a GI bleed versus 9.0±10.1 days in those with a bleed; in those age >80 years the equivalent figures were 3.1±6.6 days and 15.1±17.0 days respectively. For stable angina patients' length of stay increased from 1.0±4.3 days to 5.3±7.7 days and for STEMI from 3.9±6.4 days to 11.3±15.1 days.
In-hospital GI bleed was associated with an increased mortality at 30 days (18.8% vs 2.2%, p<0.001), in-hospital MACE (19.0% vs 1.6%, p<0.001), blood transfusion (35.1% vs 0.2%, p<0.001) and platelet transfusion (2.5% vs 0.03%, p<0.001), see Table 1. Survival at 30 days, 1 year and 5 years was worse in patients with GI bleeding (p<0.001), see Figure 2.
Using a multivariate analysis, the strongest independent predictors of GI bleeding were STEMI, OR 7.28 (95% CI 4.82-11.00), glycoprotein IIb/IIIa inhibitor use, OR 3.42 (95% CI 2.76-4.24) and receipt of circulatory support, OR 2.65 (95% CI 1.90-3.71), see Table 2. The prognostic impact of in-hospital GI bleeding is shown in Table 3. After adjustment for confounding, GI bleeding was associated with an increased odds ratio of 30-day mortality (OR 2.08 (95% CI 1.53-2.83)) and 3.7-fold increase in in-hospital MACE (OR 3.68 (95% CI 2.75-4.93)). When the subgroup of patients who received a blood transfusion were analyzed, there was a significant increase in 30-day mortality (OR 2.35 (95% CI 1.60-3.45)) and in-hospital MACE (OR 3.66 (95% CI 2.52-5.31)). Similarly, amongst patients who did not receive transfusion there was a significant increase in 30-day mortality (OR 2.01 (95% CI 1.26-3.19)) and in-hospital MACE (OR 4.31 (95% CI 2.77-6.71)). Figure 3 examines whether a legacy effect exists following an in-hospital GI bleed, and shows that amongst patients that survived at 30 days, mortality was greater in those that sustained an in-hospital GI bleeding complication compared to those patients that did not. After adjustment, this association remained significant with an increased risk of mortality in patients who sustained an in-hospital GI bleed, in comparison to those with no GI bleeding event (HR 1.49, 95% CI 1.07-2.09; p=0.02). Several variables including gastrointestinal bleed, comorbidities, moderate or poor left ventricular ejection fraction, cardiogenic shock, receipt of circulatory support, receipt of ventilation, diagnosis of NSTEMI/UA, STEMI, left main PCI, triple vessel disease and warfarin use were predictors of mortality at 1 year among survivors at 30 days (Supplementary Table 7).
Discussion
Our results suggest that in England and Wales, in-hospital GI bleeding after PCI is a rare event, but with large variations in incidence amongst subgroups of patients, i.e. octogenarian, women and STEMI patients. However, this rate is markedly less than in other studies of patients undergoing PCI, where the reported rate is between 0.97%-1.2% ADDIN EN.CITE 7,15. The overall rate of GI bleeding is stable over time, although GI bleeds that complicate PCI for STEMI have decreased significantly. This may relate to changes in pharmacotherapy, such as decline in use of thrombolysis and glycoprotein IIb/IIIa inhibitor use, during the period analyzed. In-hospital GI bleeding is independently associated with 30-day mortality with a legacy effect for increased mortality at 1-year which conferred a heightened risk even amongst those patients who survived at 30 days. 
We observed that patients who have sustained GI bleeds were older with a greater prevalence of cardiovascular risk factors and with more unstable presentations (STEMI, cardiogenic shock and/or receiving circulatory support) and may relate to the physical stress of critical illness. The observation that the need for circulatory support is a predictor of in-hospital GI bleeding may be because shock and low cardiac output, in addition to the vasoconstrictive effect secondary to the administration of inotropic drugs, may inhibit GI motility16. Moreover, prolonged mechanical ventilation has been shown to be a predictor of stress ulcers which may result in a GI bleed17. Moreover, critically ill patients are at increased risk of developing stress-related GI mucosal ulceration ADDIN EN.CITE 18.
Patients who developed a GI bleed were more likely to be treated with anti-thrombotic medications (glycoprotein IIb/IIIa inhibitors, warfarin and thrombolysis) and the marked decline in bleeding amongst patients presenting with STEMI may be related to the decline in the use of thrombolysis (from 15.6% in 2007 to 0.6% in 2014) and glycoprotein IIb/IIIa inhibitor drugs (from 31.3% in 2007 to 15.5% in 2014), probably due to a change in guidelines19. Notably, patients who had not been exposure to PCI were at increased risk of in-hospital GI bleeds and may reflect that such new patients are “unprepared” for dual antiplatelet therapy and thus are at higher risk of GI bleed compared to patients with previous PCI20. Furthermore, patients with a previous history of PCI may also be treated with a PPI prior to PCI that may protect against GI bleeds. However, it was interesting to note that clopidogrel and prasugrel were not independently associated with GI bleeding when controlling for confounding factors.
The long-term prognostic impact of GI bleeding has been examined in relation to GI bleeding per se and secondary PCI. With respect to the former, the reported excess mortality following GI bleeding varies from 2.5% at 28-days to 15.8 - 29% at 34 months ADDIN EN.CITE 21-23. Following PCI, in the U.S. analysis of the Nationwide Inpatient Sample, GI bleeding was associated with an in-hospital mortality of 9.7% and an OR of 2.63 (95% CI 2.39-2.90). ADDIN EN.CITE 7 Our current study suggests a much higher crude mortality rate of 18% but after adjustments was associated with a 2-fold increase in odds for mortality and that this increased risk also extends into the longer term. The reasons for this excess long-term mortality remain an area of controversy although GI bleed may be a surrogate marker for an overall deterioration in health and coexisting comorbidities which in themselves are life limiting ADDIN EN.CITE 24,25. Laursen et al., in case control study, compared the causes of death between those who had had an peptic ulcer bleeding and those that did not26. They demonstrated that whilst patients with UGIB have an excess mortality due to higher levels of comorbidity, the causes of that mortality were similar between the two groups. The prognostic impact of GI bleeding after PCI depends on the severity of the bleed. In our study, we were not able to directly determine the severity of the GI bleeding event with a validated scoring system, such as the Glasgow Blatchford Score,27 or the Rockall Score,28 we postulate that receipt of transfusion of a blood product may represent a surrogate marker of bleeding severity. However, a recent study suggests that a restrictive red blood transfusion approach is associated with a reduction in all-cause mortality (relative risk 0.65, 95% CI 0.44-0.97, p=0.03) and re-bleeding rates (relative risk 0.58, 0.4-0.84, p=0.004).29 Interestingly, the relationship between GI bleed and adverse outcomes (in-hospital MACE and 30-day mortality) was similar irrespective of whether the patient received transfusion of a blood product. 
Putatively, there are several mechanisms why a GI bleed is associated with mortality in patients who have had PCI. Significant loss of blood from the GI bleeding in the context of PCI may cause hemodynamic compromise resulting in death, but may also worsen myocardial ischemia or cause renal injury. Treatment of a GI bleed may also involve receipt of a blood transfusion that is associated with increases in the risk of mortality or MACE independent of the bleeding event, or may lead to interruption of antiplatelet therapy and lead to risk of thrombotic events such as stent thrombosis. ADDIN EN.CITE 30 
We are the first to describe a legacy effect in which patients with in-hospital GI bleed who survived to 30 days, in that long-term mortality risk remained increased compared to those who did not sustain a GI bleed but survived to 30 days. Possible factors that may influence this include discontinuation of dual antiplatelet therapy or use of less potent dual anti-platelet regimes which lead to increased thrombotic risk and mortality which is in agreement with previous studies.24 The Oxford Vascular Study evaluated first bleeding events amongst patients who were taking anti-platelet therapy for cardiovascular prevention following transient ischemic attack, ischemic stroke and myocardial infarction.21 In this prospective population-based cohort study of over 3,000 patients, PPI therapy was shown to be beneficial in the elderly population which may be at high risk for GI bleed, with a reported number needed to treat to avoid one bleeding event of 25. In our current study, information on PPI therapy was not available but it is likely that patients are not routinely started on PPI therapy after PCI. Published bleeding risk prediction scores have been developed to predict bleeding post PCI and acute coronary event. ADDIN EN.CITE 31,32 While these scores are not specifically risk stratify for GI bleeding per se, such scoring systems could be used to identify high risk individuals where less aggressive anti-thrombotic therapy may be considered as well as identifying those who may preferentially benefit from PPI therapy.
There are measures such as bleeding avoidance strategies33 that may reduce incidence gastrointestinal bleeding and/or mortality rates. Use of bleeding risk scores31,32 and tailoring therapy is important as there are options to minimize glycoprotein IIb/IIIa inhibitors, use less potent antiplatelet drugs or a Biofreedom stent which does not require a full year of dual antiplatelet therapy for patients that are classified as high risk. The simplest measure may be to consider PPI therapy peri-PCI procedure. It is likely that there will be no singular management that will reduced incidence and/or outcomes after GI bleeding and specific management needs to be individualized. 
Our study has several limitations, the most important of which is the likely under-reporting of subclinical in-hospital GI bleeding. This is due to the fact that GI bleed outcomes are self-reported in the BCIS database and the results of routine endoscopy or other investigations for covert GI bleeding that may have been performed in such cases are not recorded. Another important limitation is that the BCIS does not record information regarding the source, or severity, of GI bleeding. In addition, we were not able to determine the cause of death for patients with in-hospital GI bleeds. The BCIS dataset also does not collect information on drugs, such as the novel oral anticoagulants, which may influence rates of GI bleeding or PPI therapy received by patients although we believe that most patients who have been identified to have experienced a GI bleed would be prescribed PPI therapy. Therefore, our recommendations about use of PPI therapy as a part of bleeding avoidance strategies in high risk patients is only conjecture based on previous studies. A further limitation is that for some variables such as cardiogenic shock, circulatory support and receipt of ventilation we were unable to define if these occurred before or after GI bleed. Also, the current study lacks information about the duration of anticoagulant exposure. In addition to the increased risk from stress from critical illness, prolonged exposure to intravenous anticoagulation may be more prevalent among patients with cardiogenic shock requiring hemodynamic support and patients who are ventilated and have prolonged bed rest, which may contribute to the increased risks GI bleeding in this group. Finally, our dataset does not provide information regarding the severity of the bleed or treatment decisions made following the bleeding event. 
In conclusion, in-hospital GI bleeding after PCI is a rare but clinically important event associated with heightened mortality. The overall incidence of in-hospital GI bleeds appears to be stable over the 8-year period that we have studied, we have observed significant decreases in GI bleeds complication PCI for STEMI, which may in part reflect changes in pharmacological therapy in this group. In-hospital GI bleeding is associated with increased mortality and adverse cardiovascular outcomes with a legacy effect for increased 1-year mortality risk even amongst those patients who survived at 30 days. PPI should be considered for patients who are identified to be at potential high risk of GI bleeding.
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Figure 2: Kaplan-Meier survival curves at 30 days, 1 year and 5 years 








Table 1: Characteristics of participants
Variable	No GI bleed (n=548,818)	GI bleed (n=480)	p-value
Age	65±12	72±11	<0.001
Male sex	406,824 (74%)	327 (69%)	0.005
Body mass index	28.4±4.9	27.7±4.8	0.009




Previous MI	137,855 (28%)	113 (25%)	NS
Previous stroke	20,953 (4%)	31 (7%)	0.005
Peripheral vascular disease	25,667 (5%)	48 (10%)	<0.001
Renal disease	14,262 (3%)	37 (8%)	<0.001
Valvular heart disease	6,905 (1%)	20 (4%)	<0.001
Previous PCI	120,412 (23%)	80 (17%)	0.002
Previous CABG	45,112 (9%)	36 (8%)	NS
Left ventricular ejection fractionGoodModeratePoor	187,555 (71%)59,408 (23%)16,293 (6%)	77 (36%)93 (44%)42 (20%)	<0.001
Radial access	266,660 (50%)	202 (43%)	0.003
Cardiogenic shock	11,701 (2%)	93 (20%)	<0.001
Circulatory support	8,377 (2%)	83 (18%)	<0.001
Receipt of ventilation	7,263 (2%)	29 (6%)	<0.001
DiagnosisStable anginaNSTEMI/UASTEMI	194,609 (37%)204,222 (39%)121,170 (23%)	32 (7%)116 (25%)312 (68%)	<0.001
Target vesselLeft mainLADLCxRCAGraft	19,420 (4%)255,554 (47%)131,015 (24%)197,486 (36%)20,774 (4%)	44 (9%)219 (46%)87 (18%)191 (40%)20 (4%)	<0.0010.680.0030.080.66
Multivessel disease	103,492 (19%)	89 (19%)	0.86
Triple vessel disease	69,022 (13%)	115 (24%)	<0.001







Year20072008200920102011201220132014	58,022 (11%)62,733 (11%)65,305 (12%)67,232 (12%)70,875 (13%)74,320 (14%)74,560 (14%)75,771 (14%)	49 (10%)63 (13%)55 (11%)69 (14%)63 (13%)61 (13%)66 (14%)54 (11%)	NS
30-day mortality	11,863 (2%)	90 (18%)	<0.001
In-hospital MACE	8,581 (2%)	91 (19%)	<0.001
Blood transfusion	940 (0.2%)	167 (35%)	<0.001
Platelet transfusion	170 (0.03%)	12 (3%)	<0.001







Table 2: Univariable and multivariable predictors of GI bleed
Variable	Univariate odds ratio (95% CI)	p-value	Multivariate odds ratio (95% CI)	p-value
Age (per year)	1.06 (1.05-1.06)	<0.001	1.05 (1.04-1.06)	<0.001
Male sex	0.76 (0.62-0.92)	0.005	NS	NS







Peripheral vascular disease	2.19 (1.62-2.95)	<0.001	1.42 (1.03-1.96)	0.032
Renal disease	3.21 (2.30-4.47)	<0.001	2.02 (1.41-2.90)	<0.001
Valvular heart disease	3.36 (2.16-5.23)	<0.001	2.63 (1.65-4.21)	<0.001
Previous PCI	0.69 (0.54-0.87)	0.002	NS	NS
Previous CABG	0.89 (0.63-1.25)	0.49	NS	NS
Left ventricular ejection fractionGoodModeratePoor	1.00 (ref) 3.08 (2.36-4.03)5.98 (3.96-9.02)	<0.001 <0.001	1.00 (ref) 1.50 (1.11-2.02) NS	0.009 NS
Radial access	0.77 (0.64-0.92)	0.004	NS	NS
Cardiogenic shock	10.90 (8.69-13.68)	<0.001	1.73 (1.23-2.44)	0.002
Circulatory support	13.48 (10.66-17.03)	<0.001	2.65 (1.90-3.71)	<0.001
Receipt of ventilation	4.36 (3.00-6.32)	<0.001	NS	NS
DiagnosisStable anginaNSTEMI/UA
STEMI	1.00 (ref)3.44 (2.31-5.10)15.72 (10.93-22.62)	<0.001	1.00 (ref)2.47 (1.65-3.68) 7.28 (4.82-11.00)	<0.001
Target vesselLeft mainLADLCxRCAGraft	2.75 (2.02-3.75) NS 0.71 (0.56-0.89) NS NS	<0.001 NS 0.003 NS NS	1.61 (1.10-2.36) NS NS NS NS	0.015NSNSNS
NS
Multivessel disease	NS	NS	NS	NS
Triple vessel disease	2.19 (1.78-2.70)	<0.001	1.27 (1.01-1.59)	0.038











Table 3: Risk of adverse outcome with GI bleed
Group	Analysis	n	Odds ratio (95% CI)	p-value
Whole cohort	Univariate 30-day mortality	549,298	10.44 (8.30-13.14)	<0.001
	Multivariate 30-day mortality	549,298	2.08 (1.53-2.83)	<0.001
	Univariate in-hospital MACE	549,298	14.73 (11.71-18.52)	<0.001
	Multivariate in-hospital MACE	549,298	3.68 (2.75-4.93)	<0.001
Receipt of transfusion	Univariate 30-day mortality	549,131	9.86 (7.38-13.18)	<0.001
	Multivariate 30-day mortality	549,131	2.35 (1.60-3.45)	<0.001
	Univariate in-hospital MACE	549,131	13.13 (9.78-17.61)	<0.001
	Multivariate in-hospital MACE	549,131	3.66 (2.52-5.31)	<0.001
No transfusion	Univariate 30-day mortality	548,989	12.93 (9.01-18.55)	<0.001
	Multivariate 30-day mortality	548,989	2.01 (1.26-3.19)	0.003
	Univariate in-hospital MACE	548,989	19.86 (13.97-28.23)	<0.001
	Multivariate in-hospital MACE	548,989	4.31 (2.77-6.71)	<0.001


















































Supplementary Table 2: STROBE Statement—Checklist of items that should be included in reports of cohort studies 
	Item No	Recommendation	Page No
 Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1,2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction	
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	3
Methods	
Study design	4	Present key elements of study design early in the paper	3-5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	3-5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	3-5
		(b) For matched studies, give matching criteria and number of exposed and unexposed	-
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	3-5
Data sources/ measurement	8*	 For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	3-5
Bias	9	Describe any efforts to address potential sources of bias	3-5
Study size	10	Explain how the study size was arrived at	3-5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	3-5
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	3-5
		(b) Describe any methods used to examine subgroups and interactions	3-5
		(c) Explain how missing data were addressed	3-5
		(d) If applicable, explain how loss to follow-up was addressed	3-5
		(e) Describe any sensitivity analyses	3-5
Results	
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	4-7
		(b) Give reasons for non-participation at each stage	Supplementary Figure
		(c) Consider use of a flow diagram	Supplementary Figure
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	4-7
		(b) Indicate number of participants with missing data for each variable of interest	4-7
		(c) Summarise follow-up time (eg, average and total amount)	4-7
Outcome data	15*	Report numbers of outcome events or summary measures over time	4-7
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	4-7
		(b) Report category boundaries when continuous variables were categorized	4-7
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	4-7
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	4-7
Discussion	
Key results	18	Summarize key results with reference to study objectives	7-10
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	7-10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	7-10
Generalizability	21	Discuss the generalizability (external validity) of the study results	7-10
Other information	
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	10

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.

Supplementary Table 3: Rates of bleeding over time.

Group	2007	2008	2009	2010	2011	2012	2013	2014
Overall	49 (0.08%)	63 (0.10%)	55 (0.08%)	69 (0.10%)	63 (0.09%)	61 (0.08%)	66 (0.09%)	54 (0.07%)
Age <60	10 (0.05%)	7 (0.03%)	11 (0.05%)	7 (0.03%)	6 (0.03%)	10 (0.04%)	10 (0.04%)	10 (0.04%)
Age 60-80	32 (0.09%)	42 (0.11%)	33 (0.09%)	45 (0.12%)	38 (0.09%)	36 (0.09%)	39 (0.09%)	29 (0.07%)
Age >80	7 (0.21%)	14 (0.33%)	11 (0.21%)	17 (0.28%)	19 (0.27%)	15 (0.15%)	17 (0.21%)	15 (0.18%)
Women	15 (0.10%)	22 (0.14%)	17 (0.10%)	19 (0.11%)	16 (0.09%)	24 (0.13%)	24 (0.12%)	13 (0.07%)
Men	34 (0.08%)	41 (0.09%)	38 (0.08%)	48 (0.10%)	47 (0.09%)	37 (0.07%)	42 (0.08%)	40 (0.07%)
Stable angina	5 (0.02%)	6 (0.02%)	3 (0.01%)	2 (0.01%)	3 (0.01%)	1 (<0.01%)	8 (0.03%)	4 (0.02%)
NSTEMI/UA	9 (0.04%)	12 (0.05%)	15 (0.06%)	19 (0.08%)	15 (0.06%)	17 (0.06%)	14 (0.05%)	15 (0.05%)
STEMI	32 (0.52%)	43 (0.49%)	35 (0.29%)	42 (0.27%)	42 (0.23%)	42 (0.21%)	41 (0.20%)	35 (0.17%)
Clopiodgrel	49 (0.08%)	63 (0.10%)	55 (0.08%)	69 (0.10%)	41 (0.08%)	40 (0.08%)	41 (0.09%)	28 (0.07%)
Prasugrel	0 (0%)	0 (0%)	0 (0%)	6 (0.4%)	10 (0.21%)	10 (0.18%)	6 (0.14%)	6 (0.17%)





Supplementary Table 4: Changes in the proportion of elderly, female, diabetes and renal disease in cohort over time.

Variable	2007	2008	2009	2010	2011	2012	2013	2014	Total	p-value
Age >80 years	4,251 (7.3%)	5,214 (8.3%)	6,420 (9.8%)	7,150 (10.6%)	8,406 (11.9%)	9,238 (12.4%)	9,429 (12.6%)	9,852 (13.0%)	59,960 (10.9%)	<0.001
Female	15,039 (26.0%)	16,159 (25.8%)	16,867 (25.8%)	17,219 (25.6%)	18,234 (25.7%)	19,173 (25.8%)	19,202 (25.8%)	19,448 (25.7%)	141,341 (25.8%)	0.94
Diabetes	9,453 (17.5%)	11,091 (18.4%)	11,731 (18.5%)	12,254 (18.9%)	13,210 (19.3%)	14,358 (20.4%)	15,035 (21.2%)	15,701 (21.2%)	102,833 (19.5%)	<0.001





Supplementary Table 5: Patient characteristics according to use of glycoprotein IIb/IIIa inhibitors
Variable	No GPI (n=391,513)	GPI (n=111,950)	p-value
Age	65±12	62±12	<0.001
Male sex	287,105 (73%)	86,331 (77%)	<0.001
Body mass index	28.5±5.0	28.2±4.8	<0.001




Previous MI	107,090 (30%)	20,932 (21%)	<0.001
Previous stroke	15,985 (4%)	3,476 (3%)	<0.001
Peripheral vascular disease	18,948 (5%)	4,329 (4%)	<0.001
Renal disease	14,262 (3%)	37 (8%)	<0.001
Valvular heart disease	6,905 (1%)	20 (4%)	<0.001
Previous PCI	95,043 (25%)	15,805 (15%)	<0.001
Previous CABG	35,301 (9%)	6,325 (6%)	<0.001
Left ventricular ejection fractionGoodModeratePoor	146,954 (74%) 41,615 (21%) 10,881 (5%)	28,483 (62%) 13,711 (30%) 3,856 (8%)	<0.001
Radial access	193,700 (51%)	55,291 (50%)	0.041
Cardiogenic shock	5,739 (2%)	5,250 (5%)	<0.001
Circulatory support	3,963 (1%)	4,018 (4%)	<0.001
Receipt of ventilation	4,238 (1%)	2,645 (3%)	<0.001
DiagnosisStable anginaNSTEMI/UASTEMI	164,661 (44%)150,172 (40%)56,871 (15%)	14,190 (13%)39,561 (36%)54,663 (50%)	<0.001
Target vesselLeft mainLADLCxRCAGraft	13,809 (4%)183,065 (47%)97,786 (25%) 139,677 (36%) 15,211 (4%)	4,101 (4%) 53,449 (48%) 23,518 (21%) 42,977 (38%) 4,190 (4%)	0.03 <0.001<0.001 <0.001<0.001
Multivessel disease	74,765 (19%)	21,034 (19%)	0.021







Year20072008200920102011201220132014	34,962 (9%)41,365 (11%)43,722 (11%)47162 (12%)51,041 (13%056,582 (14%)57,128 (15%)59,551 (15%)	15,948 (14%)15,849 (14%)16,597 (15%)15,300 (14%)14,010 (13%)12,058 (11%)11,301 (10%)10,887 (10%)	<0.001
30-day mortality	6,805 (2%)	4,169 (4%)	<0.001
In-hospital MACE	4,798 (1%)	3,255 (3%)	<0.001
Blood transfusion	617 (0.2%)	437 (0.4%)	<0.001





Supplementary Table 6: Length of stay in entire cohort and in subgroups according to GI bleeding.

Group	Length of stay (days)	p-value
OverallGI bleed (n=474)No GI bleed (n=532,071)	11.3±15.02.0±5.3	<0.001
Age <60GI bleed (n=70)No GI bleed (n=179,682)	9.0±10.11.8±4.8	<0.001
Age 60-80GI bleed (n=291)No GI bleed (n=304,176)	10.3±15.02.0±5.2	<0.001
Age >80GI bleed (n=113)No GI bleed (n=48,213)	15.1±17.03.1±6.6	<0.001
FemaleGI bleed (n=146)No GI bleed (n=136,729)	11.0±12.42.3±5.5	<0.001
MaleGI bleed (n=339)No GI bleed (n=394,606)	11.4±16.12.0±5.2	<0.001
Stable anginaGI bleed (n=32)No GI bleed (n=188,433)	5.3±7.71.0±4.3	<0.001
NSTEMI/UAGI bleed (n=114)No GI bleed (n=198,026)	13.0±16.02.0±5.1	<0.001
 STEMIGI bleed (n=308)No GI bleed (n=118,933)	11.3±15.13.9±6.4	<0.001
Clopidogrel GI bleed (n=380)No GI bleed (n=429,042)	11.3±15.41.9±5.1	<0.001
Prasugrel GI bleed (n=38)No GI bleed (n=19,427)	12.5±13.23.4±6.0	<0.001





Supplementary Table 7: Multivariable predictors of mortality at 1 year among survivors at 30 days
Variable	Odds ratio (95% CI)	p-value
Gastrointestinal bleed	1.57 (1.08-2.29)	<0.001
Age (per year)	1.07 (1.07-1.07)	<0.001
Male sex	NS	NS







Peripheral vascular disease	1.59 (1.49-1.68)	<0.001
Renal disease	2.91 (2.74-3.10)	<0.001
Valvular heart disease	1.92 (1.74-2.12)	<0.001
Previous PCI	NS	NS
Previous CABG	NS	NS




Receipt of ventilation	1.55 (1.33-1.79)	<0.001
Diagnosis vs Stable anginaNSTEMI/UA
STEMI	1.56 (1.49-1.63) 2.04 (1.92-2.18)	<0.001<0.001
Target vesselLeft mainLADLCxRCAGraft	1.39 (1.28-1.51) NS NS NS NS	<0.001 NS NS NS NS
Multivessel disease	NS	NS
Triple vessel disease	1.22 (1.16-1.28)	<0.001







MI - myocardial infarction, PCI - percutaneous coronary intervention, CABG - coronary artery bypass graft, NS - not statistically significant.



